Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 13:9:228.
doi: 10.3389/fphar.2018.00228. eCollection 2018.

Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies

Lisa Accomasso  1 , Caterina Cristallini  2 , Claudia Giachino  1
Affiliations
Review

Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies

Lisa Accomasso et al. Front Pharmacol. .

Abstract

The use of nanomaterials in medicine has grown very rapidly, leading to a concern about possible health risks. Surely, the application of nanotechnology in medicine has many significant potentialities as it can improve human health in at least three different ways: by contributing to early disease diagnosis, improved treatment outcomes and containment of health care costs. However, toxicology or safety assessment is an integral part of any new medical technology and the nanotechnologies are no exception. The principle aim of nanosafety studies in this frame is to enable safer design of nanomedicines. The most urgent need is finding and validating novel approaches able to extrapolate acute in vitro results for the prediction of chronic in vivo effects and to this purpose a few European initiatives have been launched. While a "safe-by-design" process may be considered as utopic, "safer-by-design" is probably a reachable goal in the field of nanomedicine.

Keywords: nanomaterial; nanomedicine; nanosafety; risk assessment; risk minimization.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Accomasso L., Gallina C., Turinetto V., Giachino C. (2016). Stem cell tracking with nanoparticles for regenerative medicine purposes: an overview. Stem Cells Int. 2016:7920358. 10.1155/2016/7920358. - DOI - PMC - PubMed
    1. Allhoff F. (2009). The coming era of nano medicine. Am. J. Bioeth. 9, 3–11. 10.1080/15265160902985027 - DOI - PubMed
    1. Ankley G. T., Bennett R. S., Erickson R. J., Hoff D. J., Hornung M. W., Johnson R. D., et al. . (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 730–741. 10.1002/etc.34 - DOI - PubMed
    1. BBCResearch (2015). Nanotechnology in Medical Applications: The Global Market. Available online at: http://www.bccresearch.com/market-research/healthcare/nanotechnology-med....
    1. Brayden D. J., Cryan S. A., Dawson K. A., O'Brien P. J., Simpson J. C. (2015). High-content analysis for drug delivery and nanoparticle applications. Drug Discov. Today 20, 942–957. 10.1016/j.drudis.2015.04.001 - DOI - PubMed